Gene therapy of liver diseases (Q35842662)

10 August 2017

1 reference

title

Gene therapy of liver diseases (English)

1 reference

Gloria González Aseguinolaza

10 August 2017

0 references

4

object named as

Gloria Gonzalez-Aseguinolaza

1 reference

10 August 2017

Jesus Prieto

1

1 reference

10 August 2017

Cheng Qian

2

1 reference

10 August 2017

Ruben Hernandez-Alcoceba

3

1 reference

10 August 2017

Guillermo Mazzolini

5

1 reference

10 August 2017

Bruno Sangro

6

1 reference

10 August 2017

M Gabriela Kramer

7

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 July 2004

1 reference

Expert Opinion on Biological Therapy

10 August 2017

1 reference

10 August 2017

4

1 reference

10 August 2017

7

1 reference

10 August 2017

1073-1091

1 reference

Repopulation of rat liver by fetal hepatoblasts and adult hepatocytes transduced ex vivo with lentiviral vectors

10 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

A highly efficient, stable, and rapid approach for ex vivo human liver gene therapy via a FLAP lentiviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Inhibition of hepatitis B virus in mice by RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

In vivo inhibition of hepatitis B viral gene expression by antisense phosphorothioate oligodeoxynucleotides in athymic nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Progress and problems with the use of viral vectors for gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Ovine adenovirus vectors mediate efficient gene transfer to skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Expanded-capacity adenoviral vectors--the helper-dependent vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Prolonged and inducible transgene expression in the liver using gutless adenovirus: a potential therapy for liver cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Development and application of adenoviral vectors for gene therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Improved system for helper-dependent adenoviral vector production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Adeno-associated virus vectors for gene therapy: more pros than cons?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy: alpha-, beta-, gamma-, or delta-sarcoglycan gene delivered with intramuscular instillations of adeno-associated vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

AAV serotype 2 vectors preferentially integrate into active genes in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Targeted transgene insertion into human chromosomes by adeno-associated virus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

HIV-1 integration in the human genome favors active genes and local hotspots

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Kinetic analyses of stability of simple and complex retroviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Development of catheter-based procedures for transducing the isolated rabbit liver with plasmid DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Direct gene transfer into rat liver cells by in vivo electroporation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

EBV replicon vector system enhances transgene expression in vivo: applications to cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

In vivo treatment of hemophilia A and mucopolysaccharidosis type VII using nonprimate lentiviral vectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Prolonged correction of hyperlipidemia in mice with familial hypercholesterolemia using an adeno-associated viral vector expressing very-low-density lipoprotein receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

A non-immunogenic adenoviral vector, coexpressing CTLA4Ig and bilirubin-uridine-diphosphoglucuronateglucuronosyltransferase permits long-term, repeatable transgene expression in the Gunn rat model of Crigler-Najjar syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Correction of the UDP-glucuronosyltransferase gene defect in the gunn rat model of crigler-najjar syndrome type I with a chimeric oligonucleotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Correction of argininosuccinate synthetase (AS) deficiency in a murine model of citrullinemia with recombinant adenovirus carrying human AS cDNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Hepatocyte gene therapy in a large animal: a neonatal bovine model of citrullinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Prolonged metabolic correction in adult ornithine transcarbamylase-deficient mice with adenoviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Remission in models of type 1 diabetes by gene therapy using a single-chain insulin analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Gene therapy for murine mucopolysaccharidosis type VII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Long-term expression of beta-glucuronidase by genetically modified human neural progenitor cells grafted into the mouse central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Treatment of a lysosomal storage disease, mucopolysaccharidosis VII, with microencapsulated recombinant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Demonstration of feasibility of in vivo gene therapy for Gaucher disease using a chemically induced mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Ex vivo hepatic gene therapy of a mouse model of Hereditary Tyrosinemia Type I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Gene therapy progress and prospects: alpha-1 antitrypsin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

In utero gene transfer of human factor IX to fetal mice can induce postnatal tolerance of the exogenous clotting factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Treatment of lysosomal storage disease in MPS VII mice using a recombinant adeno-associated virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Enhanced secretion and uptake of beta-glucuronidase improves adeno-associated viral-mediated gene therapy of mucopolysaccharidosis type VII mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Expression of a new woodchuck IFN-alpha gene by a helper-dependent adenoviral vector in woodchuck hepatitis virus-infected primary hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Adenovirus-mediated gene transfer of interferon alpha inhibits hepatitis C virus replication in hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Immune responses to hepatitis B virus surface and core antigens in mice, monkeys, and pigs after Accell particle-mediated DNA immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

T helper 2 immunity to hepatitis B surface antigen primed by gene-gun-mediated DNA vaccination can be shifted towards T helper 1 immunity by codelivery of CpG motif-containing oligodeoxynucleotides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Coadministration of gamma interferon with DNA vaccine expressing woodchuck hepatitis virus (WHV) core antigen enhances the specific immune response and protects against WHV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Protection against woodchuck hepatitis virus (WHV) infection by gene gun coimmunization with WHV core and interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Humoral and CD4(+) T helper (Th) cell responses to the hepatitis C virus non-structural 3 (NS3) protein: NS3 primes Th1-like responses more effectively as a DNA-based immunogen than as a recombinant protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Plasmid DNA-based immunization for hepatitis C virus structural proteins: immune responses in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Hammerhead ribozyme-mediated inhibition of hepatitis B virus X gene expression in cultured cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Intracellular inhibition of hepatitis B virus S gene expression by chimeric DNA-RNA phosphorothioate minimized ribozyme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Bacterial virus phi29 pRNA as a hammerhead ribozyme escort to destroy hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Intracellular inhibition of the replication of hepatitis B virus by hammerhead ribozymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Inhibition of hepatitis B virus by hammerhead ribozyme targeted to the poly(A) signal sequence in cultured cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Inhibition of hepatitis B virus by antisense oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Antisense oligodeoxyribonucleotides inhibit the expression of the gene for hepatitis B virus surface antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

The inhibitory effects of antisense RNA on hepatitis B virus surface antigen synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Core specific antisense phosphorothioate oligodeoxynucleotides as potent and specific inhibitors of hepatitis C viral translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Inhibition of translation of hepatitis C virus RNA by 2-modified antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Inhibition of hepadnaviral replication by polyethylenimine-based intravenous delivery of antisense phosphodiester oligodeoxynucleotides to the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

In vivo inhibition of hepatitis B virus gene expression by antisense phosphorothioate oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Interference of hepatitis C virus RNA replication by short interfering RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Inhibition of HBV replication by siRNA in a stable HBV-producing cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Small Interfering RNA-Mediated Inhibition of Hepatitis C Virus Replication in the Human Hepatoma Cell Line Huh-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Inhibition of hepatitis B virus expression and replication by RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Inhibition of hepatitis C virus protein expression by RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Selective inhibition of hepatitis B virus replication by RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Characterization of hepatitis B virus core mutants that inhibit viral replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Abrogation of hepatitis C virus NS3 helicase enzymatic activity by recombinant human antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Modified apoptotic molecule (BID) reduces hepatitis C virus infection in mice with chimeric human livers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Hepatocyte growth factor gene therapy of liver cirrhosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Hepatocyte growth factor gene transfer into the liver via the portal vein using electroporation attenuates rat liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Transduction of the liver with activated Akt normalizes portal pressure in cirrhotic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

p53 and chemosensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Adenovirus-mediated p53 tumor suppressor gene therapy against subcutaneous HuH7 hepatoma cell line nodule of nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

New strategies to enhance gene therapy efficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Gene therapy by intrahepatic and intratumoral trafficking of p53-VP22 induces regression of liver tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Liver failure caused by herpes simplex virus thymidine kinase plus ganciclovir therapy is associated with mitochondrial dysfunction and mitochondrial DNA depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

A "distant" bystander effect of suicide gene therapy: regression of nontransduced tumors together with a distant transduced tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Combined gene therapy with suicide gene and interleukin-12 is more efficient than therapy with one gene alone in a murine model of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Transduction efficacy, antitumoral effect, and toxicity of adenovirus-mediated herpes simplex virus thymidine kinase/ ganciclovir therapy of hepatocellular carcinoma: the woodchuck animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Tumor-specific transcriptional targeting of suicide gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Hepatic intra-arterial delivery of a retroviral vector expressing the cytosine deaminase gene, controlled by the CEA promoter and intraperitoneal treatment with 5-fluorocytosine suppresses growth of colorectal liver metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Gene therapy strategies for tumor antiangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

A novel strategy for the generation of angiostatic kringle regions from a precursor derived from plasminogen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Suppression of angiogenesis and tumor growth by adenoviral-mediated gene transfer of pigment epithelium-derived factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

The HLA crossroad in tumor immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Costimulation of T cells for tumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

A blood-tumor barrier limits gene transfer to experimental liver cancer: the effect of vasoactive compounds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Cytokines, tumour-cell death and immunogenicity: a question of choice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Cytokines in cancer pathogenesis and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Pancreatic cancer escape variants that evade immunogene therapy through loss of sensitivity to IFNgamma-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Adenovirus-mediated CD40 ligand gene therapy in a rat model of orthotopic hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Genetic heterogeneity in the toxicity to systemic adenoviral gene transfer of interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Mouse alpha-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Dendritic cells: controllers of the immune system and a new promise for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Cytokine gene transfer into dendritic cells for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Telomerase-dependent oncolytic adenovirus for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Oncolysis of hepatic metastasis of colorectal cancer by recombinant vesicular stomatitis virus in immune-competent mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

Optimization of the Tet-on system to regulate interleukin 12 expression in the liver for the treatment of hepatic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1073

10.1517/14712598.4.7.1073

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference